Sartorius Stedim Biotech acquires U.S. start-up kSep Systems
July 06 2016 - 2:00AM
Business Wire
- Transaction to expand SSB’s
bioprocessing product portfolio with innovative single-use
centrifuges
Regulatory News:
Sartorius Stedim Biotech (SSB), a leading international supplier
for the biopharmaceutical industry, today has signed a contract to
acquire U.S. centrifuge specialist kSep Holdings, Inc. (kSep). The
privately owned company based in Morrisville, North Carolina, has
been operating on the market since 2011, and is expected to achieve
significant double-digit growth and to generate around $7 million
sales revenues and a strong double-digit EBITDA margin in 2016. The
transaction values kSep at around $28 million and will be closed by
the end of July 2016.
kSep has developed and markets single-use, fully automated
centrifugation systems used for manufacturing biopharmaceuticals,
such as vaccines, cell-based therapeutics and monoclonal
antibodies. Reinhard Vogt, member of SSB’s Board, commented,
“kSep’s centrifuges are a very innovative, single-use cell
separation technology that perfectly complements our offering for
downstream bioprocessing. Our clients will greatly benefit from the
unique ability to collect, wash and concentrate cells quickly and
reduce both the time and cost of downstream purification steps.”
SSB will retain kSep’s current leadership and staff.
“Sartorius Stedim Biotech’s strong relationships with its
customers will significantly speed up our internationalization and
business growth. SSB will provide access to considerably more
customers, especially in Asia, a market we haven’t developed yet,”
said Sunil Mehta, President and CEO of kSep.
This press release contains statements about the future
development of the Sartorius Stedim Biotech Group. We cannot
guarantee that the content of these statements will actually apply
because these statements are based upon assumptions and estimates
that harbor certain risks and uncertainties.
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international supplier of
products and services that enable the biopharmaceutical industry to
develop and manufacture drugs safely and efficiently. As a total
solutions provider, Sartorius Stedim Biotech offers a portfolio
covering nearly all steps of biopharmaceutical manufacture. The
company focuses on single-use technologies and value-added services
to meet the rapidly changing technology requirements of the
industry it serves. Headquartered in Aubagne, France, Sartorius
Stedim Biotech is quoted on the Eurolist of Euronext Paris. With
its own manufacturing and R&D sites in Europe, North America
and Asia and a global network of sales companies, Sartorius Stedim
Biotech has a global reach. The company employs approx. 4,200
people, and in 2015 earned sales revenue of 884.3 million
euros.
A profile of kSep
kSep Systems leverages its innovation, engineering, and cGMP
manufacturing expertise to provide robust and automated single-use
centrifugation solutions for the manufacturing of recombinant
therapeutics, cell therapy products, and vaccines. kSep products
solve the problems of traditional centrifugation-based systems by
providing a gentle processing environment for the concentration,
washing, and separation of cells while maintaining high recoveries.
kSep Systems, a spinoff from KBI Biopharma, Inc., was established
in 2011 and is based in Morrisville, NC.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160706005490/en/
Sartorius Stedim BiotechPetra Kirchhoff, Vice President of
Corporate
Communications+49(0)551.308.1686petra.kirchhoff@sartorius.com
WisdomTree International... (AMEX:DIM)
Historical Stock Chart
From Nov 2024 to Dec 2024
WisdomTree International... (AMEX:DIM)
Historical Stock Chart
From Dec 2023 to Dec 2024